March, Ruth

Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework

Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery

Pharmaceutical Economics and PolicyComputational Drug Discovery Methods

Cited by 1,344

Rare variant contribution to human disease in 281,104 UK Biobank exomes

Wang, Q., Dhindsa, R. S., Carss, K., Harper, A. R., Nag, A., Tachmazidou, I., Vitsios, D., Deevi, S. V. V., Mackay, A., Muthas, D., et al. (2021) · Nature

Genetic Associations and EpidemiologyGenomics and Rare Diseases

Cited by 604

Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank

Szustakowski, J. D., Balasubramanian, S., Kvikstad, E., Khalid, S., Bronson, P. G., Sasson, A., Wong, E., Liu, D., Wade Davis, J., Haefliger, C., et al. (2021) · Nature Genetics

Genetic Associations and EpidemiologyGenomics and Rare Diseases

Cited by 401

Rare variant associations with plasma protein levels in the UK Biobank

Dhindsa, R. S., Burren, O. S., Sun, B. B., Prins, B. P., Matelska, D., Wheeler, E., Mitchell, J., Oerton, E., Hristova, V. A., Smith, K. R., et al. (2023) · Nature

Genetic Associations and EpidemiologyGenomics and Rare Diseases

Cited by 193

Integrated analyses of growth differentiation factor-15 concentration and cardiometabolic diseases in humans

Lemmelä, S., Wigmore, E. M., Benner, C., Havulinna, A. S., Ong, R. M., Kempf, T., Wollert, K. C., Blankenberg, S., Zeller, T., Peters, J. E., et al. (2022) · eLife

GDF15 and Related BiomarkersGenetic Associations and Epidemiology

Cited by 28

Assessing the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases

Mitchell, J., Camacho, N., Shea, P., Stopsack, K. H., Joseph, V., Burren, O. S., Dhindsa, R. S., Nag, A., Berchuck, J. E., O’Neill, A., et al. (2025) · Nature Communications

BRCA gene mutations in cancerProstate Cancer Treatment and Research

Cited by 19